7 Results for: created: (01/2018 to 01/2018)

People

  1. Kris
    Kris
  2. Ni
    Ni
  3. Pietanza
    Pietanza
  4. Riely
    Riely
  5. Rudin
    Rudin
  6. Travis
    Travis
  7. Yu
    Yu
  8. Ahn
    Ahn
  9. Arbour
    Arbour
  10. Beal
    Beal

Groups

  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Thoracic Oncology (7)
  4. Department of Pathology and Laboratory Medicine (3)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  6. Biostatistics Service (2)
  7. Epidemiology and Biostatistics (2)
  8. GSK Faculty (2)
  9. Nursing (2)
  10. Radiology, Department of (2)
  1. "Mark Kris"
Formats
  1. Meeting Abstract (5)
  2. Book Section (1)
  3. Journal Article (1)
Groups
  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Thoracic Oncology (7)
  4. Department of Pathology and Laboratory Medicine (3)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  6. Biostatistics Service (2)

More Groups

People
  1. Mark Kris (7)
  2. Ai Ni (2)
  3. Charles Rudin (2)
  4. Gregory Riely (2)
  5. Helena Yu (2)
  6. Maria Pietanza (2)

More People

Years
  1. 2018 (1)
  2. 2017 (5)
  3. 2011 (1)
Publications
  1. Journal of Thoracic Oncology (5)
  2. Cancer (1)
  3. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 9th ed (1)
Publishers
  1. Elsevier Inc. (5)
  2. Wiley Blackwell (1)
  3. Wolters Kluwer Health | Lippincott Williams & Wilkins (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
    Journal Article

    Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Phase 1 study of ramucirumab or necitumumab in combination with osimertinib (AZD9291) in advanced T790M-positive EGFR-mutant NSCLC
    Meeting Abstract

    Planchard, D.; Kris, M.; Besse, B.; Hozak, R.; He, S.; Gan, F.; Wolff, K.; Chao, B.; Yu, H.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non small cell lung cancer (NSCLC)
    Meeting Abstract

    Owen, D.; Bunn, P. Jr; Johnson, B.; Kwiatkowski, D.; Kris, M.; Wistuba, I.; Gandhi, M.; Phan, S.; Shames, D.; Schulze, K.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Neratinib +/- temsirolimus in HER2-mutant lung cancers: An international, randomized phase II study
    Meeting Abstract

    Gandhi, L.; Besse, B.; Mazieres, J.; Waciar, S.; Cortot, A.; Barlesi, F.; Quoix, E.; Otterson, G.; Ettinger, D.; Horn, L.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Improved small cell lung cancer (SCLC) response rates with veliparib and temozolomide: Results from a phase II trial
    Meeting Abstract

    Byers, L. A.; Krug, L.; Waqar, S.; Dowlati, A.; Hann, C.; Chiappori, A.; Owonikoko, T.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Small cell and neuroendocrine tumors of the lung
    Book Section

    Krug, L. M.; Pietanza, M. C.; Kris, M. G.; Rosenzweig, K.; Travis, W. D.
    In DeVita, V. T. Jr; Lawrence, T. S.; Rosenberg, S. A. (Eds.) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 9th ed (2011)

    Fulltext@MSK | Save